References for: association

Full identifier: http://purl.org/np/RA6DZEXFDgm-OEzwFADR6Bzkk9jrep63I5M_t6LlSpiqs#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
"Zolmitriptan is contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c Warnings and Precautions ( 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 Ischemic bowel disease [see Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see Drug Interactions ( 7.2 Clinical Pharmacology ( 12.3 Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 History of coronary artery disease (CAD) or coronary vasospasm ( 4 Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 Monamine oxidase (MAO)-A inhibitor used in past 2 weeks ( 4 Known hypersensitivity to zolmitriptan ( 4"
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T16:00:23.548Z